Japan suspends 1.63 mn doses of Moderna vaccine over contamination

Japan suspended use of about 1.63 million doses of Moderna vaccine Thursday after contamination was found in unused vials, raising concern of a supply shortage

Moderna Covid-19 vaccine
Agencies Tokyo
3 min read Last Updated : Aug 27 2021 | 2:33 AM IST

Japan suspended the use of 1.63 million doses of Moderna’s Covid-19 vaccine on Thursday, more than a week after the domestic distributor received reports of contaminants in some vials. Both Japan and Moderna said that no safety or efficacy issues had been identified and that the suspension was just a precaution. But the move prompted several Japanese companies to cancel worker vaccinations planned for Thursday.
 
"Moderna confirms having been notified of cases of particulate matter being seen in drug product vials of its Covid-19 vaccine," Moderna said in a statement.
 
“The firm is investigating the reports and remains committed to working expeditiously with its partner, Takeda, and regulators to address this,” it added, referring to Japan's Takeda Pharmaceutical, which distributes the vaccine in the country.
 
A Health Ministry official said Takeda first found out about the contaminated vials on August 16 and reported the issue to the government on Wednesday. The delay was because Takeda needed time to gather information on which vials were affected and where they were in the country, the official said.
 
Moderna said the contamination could be due to a manufacturing issue in one of the production lines at its contract manufacturing site in Spain. Spanish pharma company Rovi, which bottles or "fills and finishes" Moderna vaccines for markets other than the United States, said it is investigating possible contamination of Moderna doses and the issue appeared to be limited to a few batches bound for Japan.
 
Shares in Rovi dropped 4.6 per cent. The suspension is a fresh setback for Moderna, whose partners had production delays last month that disrupted supplies to countries, including South Korea.Moderna and Takeda did not immediately reply to Reuters’ requests for comment.
 
Japan's defence ministry, which operates a mass vaccination site in Osaka, said shots from the lot in question, which contains 565,400 doses, had been used in the western prefecture between August 6 and August 20, but it did not say how many people were affected.
 
Moderna said that “out of an abundance of caution” it had put the lot in question and two adjacent lots on hold. Takeda said it conducted an emergency examination after particulate matter was found in a lot of vaccine vials at an inoculation site.
 
Prime Minister Yoshihide Suga said on Thursday the country’s inoculation plan would be little affected by the issue. A day earlier, he said about 60 per cent of the public will be fully vaccinated by the end of September and the country had enough vaccines to provide booster doses if such a decision is taken.
 
Spain's Rovi says Moderna vaccine contamination under investigation
 
Spanish pharma company Rovi said on Thursday the potential contamination of some doses of the vaccine which it manufactures for Moderna was under investigation.
 

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :JapanCoronavirus VaccineVaccination

First Published: Aug 26 2021 | 2:16 PM IST

Next Story